Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters

Therapeutic Methods and Therapies TCIM
Database
Language
Affiliation country
Publication year range
1.
Int J Mol Sci ; 22(21)2021 Oct 28.
Article in English | MEDLINE | ID: mdl-34769090

ABSTRACT

GLOBOCAN 2020 estimated more than 19.3 million new cases, and about 10 million patients were deceased from cancer in 2020. Clinical manifestations showed that several growth factor receptors consisting of transmembrane and cytoplasmic tyrosine kinase (TK) domains play a vital role in cancer progression. Receptor tyrosine kinases (RTKs) are crucial intermediaries of the several cellular pathways and carcinogenesis that directly affect the prognosis and survival of higher tumor grade patients. Tyrosine kinase inhibitors (TKIs) are efficacious drugs for targeted therapy of various cancers. Therefore, RTKs have become a promising therapeutic target to cure cancer. A recent report shows that TKIs are vital mediators of signal transduction and cancer cell proliferation, angiogenesis, and apoptosis. In this review, we discuss the structure and function of RTKs to explore their prime role in cancer therapy. Various TKIs have been developed to date that contribute a lot to treating several types of cancer. These TKI based anticancer drug molecules are also discussed in detail, incorporating their therapeutic efficacy, mechanism of action, and side effects. Additionally, this article focuses on TKIs which are running in the clinical trial and pre-clinical studies. Further, to gain insight into the pathophysiological mechanism of TKIs, we also reviewed the impact of RTK resistance on TKI clinical drugs along with their mechanistic acquired resistance in different cancer types.


Subject(s)
Antineoplastic Agents/pharmacology , Molecular Targeted Therapy , Neoplasms/drug therapy , Protein-Tyrosine Kinases/antagonists & inhibitors , Animals , Binding Sites , Clinical Trials as Topic , Drug Evaluation, Preclinical , Humans , Neoplasms/enzymology , Protein-Tyrosine Kinases/metabolism
2.
Oxid Med Cell Longev ; 2021: 8839479, 2021.
Article in English | MEDLINE | ID: mdl-33747350

ABSTRACT

Black berry (Syzygium cumini) fruit is useful in curing diabetic complications; however, its role in diabetes-induced cardiomyopathy is not yet known. In this study, we investigated the regulation of gelatinase-B (MMP-9) by S. cumini methanol seed extract (MSE) in diabetic cardiomyopathy using real-time PCR, RT-PCR, immunocytochemistry, gel diffusion assay, and substrate zymography. The regulatory effects of MSE on NF-κB, TNF-α, and IL-6 were also examined. Identification and estimation of polyphenol constituents present in S. cumini extract were carried out using reverse-phase HPLC. Further, in silico docking studies of identified polyphenols with gelatinase-B were performed to elucidate molecular level interaction in the active site of gelatinase-B. Docking studies showed strong interaction of S. cumini polyphenols with gelatinase-B. Our findings indicate that MSE significantly suppresses gelatinase-B expression and activity in high-glucose- (HG-) stimulated cardiomyopathy. Further, HG-induced activation of NF-κB, TNF-α, and IL-6 was also remarkably reduced by MSE. Our results suggest that S. cumini MSE may be useful as an effective functional food and dietary supplement to regulate HG-induced cardiac stress through gelatinase.


Subject(s)
Anti-Inflammatory Agents/pharmacology , Hyperglycemia/pathology , Matrix Metalloproteinase 9/metabolism , Myocytes, Cardiac/pathology , Oxidative Stress , Plant Extracts/pharmacology , Seeds/chemistry , Syzygium/chemistry , Animals , Cell Line , Cell Nucleus/drug effects , Cell Nucleus/metabolism , Chromatography, High Pressure Liquid , Gene Expression Regulation, Enzymologic/drug effects , Glucose , Hyperglycemia/genetics , Inflammation/pathology , Interleukin-6/metabolism , Matrix Metalloproteinase 9/genetics , Myocytes, Cardiac/drug effects , Myocytes, Cardiac/enzymology , NF-kappa B/metabolism , Oxidative Stress/drug effects , Phenols/pharmacology , Protein Transport/drug effects , Rats , Substrate Specificity/drug effects , Thermodynamics , Tumor Necrosis Factor-alpha/metabolism
3.
Eur J Med Chem ; 125: 736-750, 2017 Jan 05.
Article in English | MEDLINE | ID: mdl-27721157

ABSTRACT

A novel series of donepezil based multi-functional agents "(E)-5,6-dimethoxy-2-(4-(4-substituted piperazin-1-yl)benzylidene)-2,3-dihydro-1H-inden-1-ones" have been designed and synthesized as potential anti-Alzheimer's agents. In-vitro studies revealed that these compounds demonstrated moderate to good AChE and Aß aggregation inhibitory activity. These derivatives are also endowed with admirable antioxidant activity. Among the entire series compounds IP-9, IP-13 and IP-15 appeared as most active multi-functional agents and displayed marked AChE inhibitory, Aß disaggregation and antioxidant activity. Studies indicate that IP-13 and IP-15 showed better AChE inhibitory activity than the standard drug donepezil and IP-9, IP-13 as well as IP-15 exhibited better Aß aggregation inhibitory activity than curcumin. These compounds (IP-9, IP-13 and IP-15) successfully diminished H2O2 induced oxidative stress in SH-SY5Y cells and displayed excellent neuroprotective activity against H2O2 as well as Aß induced toxicity in SH-SY5Y cells in a concentration dependent manner. Moreover, these derivatives did not exert any significant toxicity in neuronal SH-SY5Y cells in cytotoxicity assay. To elucidate the plausible binding mode of the compounds IP-9, IP-13 and IP-15, molecular docking studies and molecular dynamics (MD) simulation studies were also performed and the results indicate their significant interactions with the active sites of AChE as well as Aß1-42 peptide. Thus, the present study evidently showed that IP-9, IP-13 and IP-15 are potent multi-functional agents against Alzheimer's disease and might serve as promising lead candidates for anti-Alzheimer drug development.


Subject(s)
Alzheimer Disease/drug therapy , Drug Design , Indans/pharmacology , Molecular Dynamics Simulation , Piperidines/pharmacology , Acetylcholine/chemistry , Cell Line , Donepezil , Drug Delivery Systems , Humans , Indans/chemistry , Indans/therapeutic use , Ligands , Microscopy, Electron, Transmission , Molecular Structure , Neuroprotective Agents/chemistry , Neuroprotective Agents/pharmacology , Neuroprotective Agents/therapeutic use , Piperidines/chemistry , Piperidines/therapeutic use , Protein Aggregation, Pathological/drug therapy , Protein Binding/drug effects
4.
Bioorg Med Chem ; 18(7): 2491-500, 2010 Apr 01.
Article in English | MEDLINE | ID: mdl-20303771

ABSTRACT

Novel thiazolotriazolopyrimidine derivatives (23-33) designed as potential adenosine A(2A) receptor (A(2A)R) antagonists were synthesized. Molecular docking studies revealed that all compounds (23-33) exhibited strong interaction with A(2A)R. The strong interaction of the compounds (23-33) with A(2A)R in silico was confirmed by their high binding affinity with human A(2A)R stably expressed in HEK293 cells using radioligand-binding assay. The compounds 24-26 demonstrated substantial binding affinity and selectivity for A(2A)R as compared to SCH58261, a standard A(2A)R antagonist. Decrease in A(2A)R-coupled release of endogenous cAMP in treated HEK293 cells demonstrated in vitro A(2A)R antagonist potential of the compounds 24-26. Attenuation in haloperidol-induced motor impairments (catalepsy and akinesia) in Swiss albino male mice pre-treated with compounds 24-26 further supports their role in the alleviation of PD symptoms.


Subject(s)
Adenosine A2 Receptor Antagonists , Pyrimidines/chemical synthesis , Pyrimidines/pharmacology , Thiones/chemical synthesis , Thiones/pharmacology , Animals , Antipsychotic Agents/antagonists & inhibitors , Antipsychotic Agents/pharmacology , Catalepsy/chemically induced , Catalepsy/prevention & control , Cell Line , Cell Membrane/drug effects , Cell Membrane/metabolism , Chromatography, Thin Layer , Computer Simulation , Crystallography, X-Ray , Cyclic AMP/metabolism , Drug Evaluation, Preclinical , Dyskinesia, Drug-Induced/prevention & control , Haloperidol/antagonists & inhibitors , Haloperidol/pharmacology , Humans , Magnetic Resonance Spectroscopy , Male , Mice , Models, Molecular , Motor Activity/drug effects , Protein Binding , Radioligand Assay , Structure-Activity Relationship
SELECTION OF CITATIONS
SEARCH DETAIL